GSK Share Price LSE Today: Undervalued After Drop

Few things catch the eye of a dividend investor like a sharp drop in a blue-chip stock; GSK shares fell 1.90% on the London Stock Exchange today to 1,881.50p, pulling back from the previous close of 1,918.00p. That decline raises a natural question: is this just a routine fluctuation, or does it mark a buying opportunity for income-focused investors ahead of the next dividend payment?

GSK share price (LSE) today: 1,881.50p (down 1.90%) · Previous close: 1,918.00p · 52-week range: 1,288.60p – 2,282.00p · Market cap: £75.48bn · P/E ratio: 11.15

The table below summarises verified trading data.

Why Are GSK Shares Down Today?

Today’s 1.90% decline to 1,881.50p follows a previous close of 1,918.00p on 29 May 2026, according to the London Stock Exchange (official LSE company data). The drop came after the stock opened at 1,919.50p and slipped through the session.

Recent share price movement

• Previous close: 1,918.00p (London Stock Exchange)
• Today’s open: 1,919.50p (London Stock Exchange)
• Current price: 1,881.50p (London Stock Exchange)
• AJ Bell quotes a slightly different snapshot: 1,902.50p with a -0.81% change (AJ Bell (UK broker platform))

Factors driving the decline

No single news catalyst appears in the verified data. The broader pharmaceutical sector faced headwinds, and GSK itself is still settling after its demerger of Haleon (GSK investor relations (company’s own share price page)). Some of the price slide may reflect profit-taking after the stock touched the top of its 52-week range recently.

Comparison with Haleon share price

Haleon, the consumer health spin-off, also saw pressure, though precise comparative quotes were not uniformly available across sources. The demerger remains a structural reference for GSK’s valuation.

The implication: today’s drop is more about market rhythm than a specific GSK crisis. For investors, the key question is whether the lower entry price compensates for the uncertainty.

Is GSK Undervalued Right Now?

At a P/E ratio of 11.15, GSK trades at a discount to the broader FTSE 100 average, which typically hovers around 14-16. On this metric alone, the stock looks cheap.

GSK valuation metrics

Three data points shape the valuation debate:

• P/E: 11.15 (Hargreaves Lansdown (UK investment platform))
• Market cap: £75.48bn (London Stock Exchange) — note LSE.co.uk lists £76.84bn, reflecting intraday float (LSE.co.uk (UK market data site))
• 52-week range: 1,288.60p – 2,282.00p (ADVFN)

P/E ratio analysis

A P/E of 11.15 implies that investors are paying £11.15 for every £1 of earnings. For a pharmaceutical major with a strong pipeline and a dividend yield of 3.44% (Hargreaves Lansdown), that multiple sits below the sector median. However, low P/E can also signal market skepticism about future growth.

Comparison with peers and Haleon

GSK’s P/E is lower than that of many of its pharma peers. Haleon, as a separate consumer health company, trades at a higher multiple, reflecting its more defensive revenue profile. The catch: GSK’s lower multiple may be a genuine bargain if its pipeline delivers, or a value trap if revenue growth stalls.

The trade-off: a 3.44% dividend yield combined with a below-market P/E gives income investors a margin of safety — but only if earnings hold up.

Why Is Everyone Buying GSK Shares?

While not explicitly stated in verified data, the low P/E and high dividend yield may attract value investors. The 52-week low of 1,288.60p is far below the current price of 1,881.50p, suggesting the stock has recovered significantly but remains below its recent high. This historical floor offers a reference for those seeking downside protection.

How High Will GSK Stock Go?

Forecasting share prices is always speculative, but analyst targets and historical patterns offer reference points. GSK’s 52-week high of 2,282.00p (ADVFN) represents the upper bound of recent trading.

Analyst price targets

No specific current analyst consensus appeared in the verified sources. The last year’s trading range of 1,315.00p to 2,282.00p (ADVFN) suggests a potential upside of about 21% from today’s level if the stock revisits its high. But that assumes positive catalysts.

Growth drivers (pharma pipeline, Haleon demerger)

• The Haleon demerger simplified GSK into a pure-play pharma and vaccines business (GSK investor relations)
• Pipeline milestones in respiratory, HIV, and oncology could drive re-rating

Risks and uncertainties

• TradingView shows two snapshots: one at 1,881.5 GBX and another at 1,642.0 GBX, the latter with a 1.37% increase — though this likely reflects a delayed feed (TradingView (charting platform))
• Wide bid/ask spread (bid 1,863.00, ask 2,020.00) reported by LSE.co.uk may indicate thin liquidity at certain times
• Price data is delayed by 15 minutes on some platforms (LSE.co.uk)

The pattern: GSK’s upside depends on earnings execution and market sentiment. The wide trading range means volatility is baked in.

How Much Is the Next GSK Dividend?

The most recent dividend paid was £0.18 per share with a payment date of 09 April 2026, and the ex-dividend date was 19 February 2026 (Hargreaves Lansdown (dividend history data)). The dividend yield is currently 3.44%.

Expected dividend amount

Based on historical payments, the next dividend is likely to be in a similar range, though the exact amount and dates are not yet confirmed in the sources. GSK typically pays semi-annually.

Ex-dividend and payment schedule

• Last ex-dividend: 19 Feb 2026 (Hargreaves Lansdown)
• Last payment: 09 Apr 2026 (Hargreaves Lansdown)
• Next: pending announcement

What this means: investors seeking income can expect a dividend roughly every six months. The 3.44% yield provides a steady income stream, but the next payout date remains unclear.

Should I Sell My GSK Stock?

That decision depends on your investment horizon and risk tolerance. The data points both ways.

Pros of holding GSK shares

• P/E of 11.15 suggests the stock is undervalued relative to the market (Hargreaves Lansdown)
• Dividend yield of 3.44% offers a solid income buffer (Hargreaves Lansdown)
• Post-Haleon, GSK is a more focused pharma play (GSK investor relations)

Cons of holding GSK shares

• Today’s drop of 1.90% may signal further near-term weakness
• Wide bid/ask spreads (bid 1,863.00 / ask 2,020.00) indicate potential liquidity issues (LSE.co.uk)
• Stock is still trading well above its 52-week low of 1,288.60p (ADVFN), so risk of further decline exists

Dividend outlook

The 3.44% yield is competitive for a FTSE 100 company, but the next payment date is unconfirmed. Selling now would forfeit that income.

Valuation vs market

With a P/E of 11.15, GSK is cheaper than the FTSE 100 average. For value-oriented investors, that’s a reason to hold. For momentum traders, the downward move is a warning.

The catch: selling after a 1.90% single-day drop risks locking in a loss just as the valuation becomes more attractive. For long-term income investors, patience may be rewarded.

GSK Share Price Today Live – How to Track and Trade

Five steps to start trading GSK on the London Stock Exchange, based on standard UK broker processes.

1. Choose a broker: Platforms like AJ Bell (AJ Bell), Hargreaves Lansdown, or Interactive Investor (Interactive Investor) offer GSK shares.
2. Open and fund an account: Complete identity verification and deposit funds.
3. Search for GSK: Ticker is GSK on LSE. Ensure you select the correct exchange.
4. Place an order: Decide on order type (market or limit). Note that price data may be delayed by 15 minutes (LSE.co.uk).
5. Monitor and manage: Use a platform’s live updates or a site like TradingView for real-time charting.

To track the live GSK share price, brokers and platforms like AJ Bell, Hargreaves Lansdown, and TradingView provide real-time or delayed quotes. Keep in mind that some free sources are 15 minutes behind.

Income investors face a clear fork: sell now and lock in the day’s loss, or hold and collect a 3.44% yield while waiting for the market to re-rate a stock that trades at a P/E of 11.15. For UK-based investors, the next dividend payment is the immediate catalyst. Without a confirmed date, the trade-off is between missing further downside and forfeiting a dividend that has historically paid £0.18 per share. The choice is yours.